Lake Morrison, MD
Enriched profileAssociate Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine · Duke University School of Medicine
Lake Morrison is Associate Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine at Duke University School of Medicine. OpenAlex indexes 46 publications with 3,869 citations (h-index 23); ClinicalTrials.gov lists 5 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 1 Sept 2026
Lake Morrison, MD, is Associate Professor of Medicine, Division of Pulmonary, Allergy, and Critical Care Medicine at Duke University School of Medicine / Duke University Health System (Durham, NC). The public record shows 46 publications with 3,869 citations (h-index 23), centered on Idiopathic Pulmonary Fibrosis. It also documents an investigator role on 5 registered clinical trials, industry payments reported by 2 companies.
- Top research focus: Idiopathic Pulmonary Fibrosis
- 5 registered trials on ClinicalTrials.gov
- Open Payments reporting from 2 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 5 registered studies on ClinicalTrials.gov. The most recent:
- Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry
Sponsor: Duke University
- AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis
Sponsor: Duke University
Industry payments
Updated 1 Sept 2026
2 companies reported payments to CMS in program years 2021–2024. These are public disclosures, not judgments. The latest:
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20243 payments
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year202315 payments$20,507openpaymentsdata.cms.gov ↗
- Boehringer Ingelheim Pharmaceuticals, Inc.Program year20228 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
36.9%Kinase inhibitor22.7%Ofev100%Part D≥18 patientsPyridone11.2%Pirfenidone81%Esbriet19%Part D<11 patientsMetabolism & gastrointestinal
33.8%Corticosteroid30.5%Prednisone100%Part D≥61 patientsProton pump inhibitor3.2%Omeprazole100%Part D<11 patientsRespiratory
15.1%beta2-Adrenergic Agonist8.3%Albuterol Sulfate Hfa78%Ventolin Hfa22%Part D<11 patientsCorticosteroid5%Trelegy Ellipta55%Breo Ellipta45%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Hyperpolarized129Xe MRI Membrane Uptake Associates With 12-month Changes in Lung Function in Patients With Idiopathic Pulmonary Fibrosis Initiating Therapy
American Journal of Respiratory and Critical Care Medicine
2025
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/lake-morrison-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
Mentions by others
where others cite or feature them- Other
scholars.duke.edu/person/lake.morrison
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗ - Other
dukehealth.org/find-doctors-physicians/lake-d-morrison-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →dukehealth.org ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- Pulmonary and Critical Care Medicine Fellowship
Hospital of the University of Pennsylvania and affiliated hospitals
2004provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholars.duke.edu ↗
- Board Certified
Pulmonary Disease, American Board of Internal Medicine
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
Editorial & leadership roles
journal and society appointments- Program Director
Duke Interstitial Lung Disease Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.duke.edu ↗ - provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →scholars.duke.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
William Kraus, MD
Duke University School of Medicine
Angeles Secord, MD
Duke University School of Medicine
Virginia Kraus, MD, PhD
Duke University School of Medicine
Neal Ready, MD
Duke University School of Medicine